Atea Pharmaceuticals, Inc. (AVIR)
3.945
-0.04
(-1.13%)
USD |
NASDAQ |
Nov 19, 16:00
3.945
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Enterprise Value : 129.39M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 129.39M |
| November 17, 2026 | 126.98M |
| November 16, 2026 | 139.83M |
| November 13, 2026 | 154.28M |
| November 12, 2026 | 147.06M |
| November 11, 2026 | 147.86M |
| November 10, 2026 | 146.25M |
| November 09, 2026 | 163.12M |
| November 06, 2026 | 155.09M |
| November 05, 2026 | 147.86M |
| November 04, 2026 | 167.13M |
| November 03, 2026 | 143.84M |
| November 02, 2026 | 138.22M |
| October 30, 2026 | 139.03M |
| October 29, 2026 | 155.09M |
| October 28, 2026 | 151.87M |
| October 27, 2026 | 143.84M |
| October 26, 2026 | 143.04M |
| October 23, 2026 | 133.41M |
| October 22, 2026 | 134.21M |
| October 21, 2026 | 136.62M |
| October 20, 2026 | 167.53M |
| October 19, 2026 | 161.51M |
| October 16, 2026 | 155.89M |
| October 15, 2026 | 172.75M |
| Date | Value |
|---|---|
| October 14, 2026 | 180.78M |
| October 13, 2026 | 208.88M |
| October 12, 2026 | 212.90M |
| October 09, 2026 | 222.53M |
| October 08, 2026 | 222.94M |
| October 07, 2026 | 211.29M |
| October 06, 2026 | 216.11M |
| October 05, 2026 | 220.93M |
| October 02, 2026 | 220.93M |
| October 01, 2026 | 218.52M |
| September 30, 2026 | 227.35M |
| September 29, 2026 | 196.42M |
| September 28, 2026 | 198.02M |
| September 25, 2026 | 195.62M |
| September 24, 2026 | 195.62M |
| September 23, 2026 | 204.44M |
| September 22, 2026 | 233.31M |
| September 21, 2026 | 216.47M |
| September 18, 2026 | 208.45M |
| September 17, 2026 | 202.84M |
| September 16, 2026 | 194.01M |
| September 15, 2026 | 200.43M |
| September 14, 2026 | 207.65M |
| September 11, 2026 | 206.85M |
| September 10, 2026 | 196.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -50.95M |
| CorMedix, Inc. | 147.26M |
| Eloxx Pharmaceuticals, Inc. | -13.73M |
| Breakthrough Chemistry, Inc. | 0.1965M |
| BioStem Technologies, Inc. | 15.46M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.16M |
| Total Expenses (Quarterly) | 32.16M |
| EPS Diluted (Quarterly) | -0.4009 |
| Earnings Yield | -49.69% |
| Normalized Earnings Yield | -49.69 |